Clinical · primary care

CGM for Type 2 Diabetes in Primary Care

6 min read · Updated July 2026

Continuous glucose monitoring (CGM) is no longer only for people on intensive insulin. As guidance evolves, primary-care teams are using CGM to surface the day-to-day glucose patterns that a single HbA1c cannot show, in the setting where most type 2 diabetes is actually managed. This article summarizes what the evidence broadly supports, why metrics like time in range matter, and how a primary-care team can get started.

Why CGM is moving beyond insulin users

The majority of people living with type 2 diabetes are cared for in primary care, not in specialty clinics. Historically, CGM adoption concentrated among people on multiple daily insulin injections or pumps, where real-time glucose data helps avoid hypoglycemia and guides dosing. That framing is shifting.

The reason is simple: HbA1c is an average. Two people with the same A1c can have very different days, one with steady glucose and another swinging between highs after meals and lows overnight. HbA1c hides that variability, and it can also be distorted by conditions affecting red blood cells. CGM makes the underlying pattern visible, showing when glucose rises, how high, and for how long. For someone managed with lifestyle changes, metformin, or other non-insulin agents, that visibility can turn abstract advice into something concrete a patient can see and act on. If you want a plain-language primer for patients, our page for individuals covers the basics.

What the evidence shows

The direction of the evidence has been encouraging, but it should be read with care. The American Diabetes Association's Standards of Care have increasingly recognized a role for CGM in type 2 diabetes, including for people not on intensive insulin, and this guidance is updated regularly. Randomized studies, including trials conducted in primary-care settings, have generally reported improvements in glycemic measures such as time in range and A1c when CGM is added to usual care for non-insulin type 2 diabetes.

Because study designs, populations, and follow-up periods vary, the size of any benefit differs across trials, and CGM is not a substitute for the fundamentals of diabetes care. Treat these findings as a general signal rather than a fixed number, and confirm specifics against the current ADA Standards of Care and other relevant guidelines, which continue to evolve.

What consistently emerges is the value of metrics beyond A1c. Time in range (the share of readings within target) and glucose variability describe the quality of glucose control in a way an average cannot. These measures often resonate with patients because they connect directly to the choices they make each day. For background on why abnormal glucose patterns matter even before diabetes is diagnosed, see our related reading on what dysglycemia is.

How a primary-care team can start

Getting started does not require a specialty program. A practical sequence looks like this:

Identify candidates. Consider people with type 2 diabetes who are above target, recently diagnosed and building habits, changing therapy, or struggling to connect their routines to their numbers, alongside those on insulin who already qualify.
Order the sensor. Depending on your setting, this may be a prescription filled at a pharmacy or supplied through the clinic. Confirm coverage criteria before you order, since payer policies differ and change over time.
Read the ambulatory glucose profile (AGP). The standardized AGP report condenses days of data into one view. Focus first on time in range, then on the shape of the curve, where lines cluster high and where they dip.
Act on the patterns. Post-meal spikes may point to food choices or timing; overnight highs or lows can inform medication adjustments; steady variability may reinforce what is working. Small, specific changes tied to a visible pattern tend to stick.

Even a short, time-limited period of wearing a sensor can be enough to reveal patterns and motivate change, which suits the pace of a busy primary-care panel.

The workflow problem

The obstacle is rarely the science; it is time. Reviewing AGP reports one patient at a time, spotting who is trending in the wrong direction, and deciding who needs attention this week does not scale well across a full panel. Manual review is thorough but slow, and it competes with everything else a primary-care visit has to cover.

This is where automated decision support helps. Rather than replacing clinical judgment, it triages the panel, flagging the patients whose glucose patterns warrant a closer look so that limited clinician time goes where it matters most. For more on the tools and guidance available, browse our resources.

See how Endobits automates CGM review

Endobits reads CGM data across your panel and surfaces the patients who need attention, so review becomes triage instead of a report-by-report slog.

For clinical GPs

Educational content for healthcare professionals; not medical advice. Endobits is clinical decision-support, not a medical device. Verify current clinical guidance (including the ADA Standards of Care) and payer policies, which change over time.